967 Inflammatory tumour microenvironment in CRC alters macrophage function through mesenchymal stromal cell PD-1/PD-L1 signalling

967 Inflammatory tumour microenvironment in CRC alters macrophage function through mesenchymal stromal cell PD-1/PD-L1 signalling

Bibliographic Details
Main Authors:	Laurence Egan, Philip Dunne, Niamh Leonard, Oliver Treacy, Hannah Egan, Thomas Ritter, Daniela Loessner, Margaret Sheehan, Sean Hynes, Aisling Hogan, Aideen E Ryan, Keara Redmond, Aoife Canney, Shania Corry, Eileen Reidy
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2023-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

1436 Targeting stromal cell sialylation to overcome tumour-induced immunosuppressive effects on NK cells in colorectal cancer
by: Oliver Treacy, et al.
Published: (2023-11-01)

CBX3 antagonizes IFNγ/STAT1/PD-L1 axis to modulate colon inflammation and CRC chemosensitivity
by: Yao Xiang, et al.
Published: (2024-04-01)

BTLA and PD-1 signals attenuate TCR-mediated transcriptomic changes
by: Muhammad Zainul Arifin, et al.
Published: (2025-02-01)

BTLA and PD-1 signals attenuate TCR-mediated transcriptomic changes
by: Muhammad Zainul Arifin, et al.
Published: (2024-07-01)

Efficacy and challenges of anti-PD1 in MSI-H mCRC: a case report on concurrent infections and ir-AIHA
by: Xiaxia Pei, et al.
Published: (2024-08-01)

نقش PD-1/ PD-L1 و Anti-PD-1/ PD-L1 در پیشرفت و سرکوب سرطان
by: نرگس عبدالهی, et al.
Published: (2023-11-01)

Author Correction: CBX3 antagonizes IFNγ/STAT1/PD-L1 axis to modulate colon inflammation and CRC chemosensitivity
by: Yao Xiang, et al.
Published: (2024-09-01)

Regulatory mechanisms of PD-1/PD-L1 in cancers
by: Xin Lin, et al.
Published: (2024-05-01)

Progress of research on PD-1/PD-L1 in leukemia
by: Huizhen Cao, et al.
Published: (2023-09-01)

Ocular adverse events in PD-1 and PD-L1 inhibitors
by: James Murray, et al.
Published: (2021-07-01)

PD-1 and PD-L1 expression in rare lung tumors
by: Marton Gyulai, et al.
Published: (2023-05-01)

The significance of PD-1/PD-L1 imbalance in ulcerative colitis
by: Wei Shi, et al.
Published: (2023-05-01)

Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis
by: Fabian Krutzek, et al.
Published: (2022-06-01)

PD-1/PD-L1 and DNA Damage Response in Cancer
by: Mateusz Kciuk, et al.
Published: (2023-02-01)

Conflict and war in the Middle East, l967-91 : regional dynamic and the superpowers /
by: 201426 Tibi, Bassam, et al.
Published: (1993)

Gradient material Pd-PdHx
by: M. V. Goltsova, et al.
Published: (2018-10-01)

Research progress and challenges of the PD-1/PD-L1 axis in gliomas
by: Dong Jiacheng, et al.
Published: (2024-09-01)

PD-L1 and PD-1 in immune regulation and their implications in blood cancers
by: Parisa Shiri Aghbash, et al.
Published: (2024-10-01)

The PD-L1/PD-1 Axis Blocks Neutrophil Cytotoxicity in Cancer
by: Olga Yajuk, et al.
Published: (2021-06-01)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
by: Kazuhiko Hashimoto, et al.
Published: (2020-07-01)

Peptide Blockers of PD-1-PD-L1 Interaction Reinvigorate PD-1-Suppressed T Cells and Curb Tumor Growth in Mice
by: Shanshan (Jenny) Zhong, et al.
Published: (2024-07-01)

Tumor‐derived exosomal PD-L1: a new perspective in PD-1/PD-L1 therapy for lung cancer
by: Yunjiao Wu, et al.
Published: (2024-03-01)

272 PD-L1 CAR engineered K-NK cells to target PD-L1+ or PD-L1- tumors
by: Pedro Romero, et al.
Published: (2023-11-01)

Robust Preanalytical Performance of Soluble PD-1, PD-L1 and PD-L2 Assessed by Sensitive ELISAs in Blood
by: Kimberly Krueger, et al.
Published: (2022-10-01)

P967: TUMOR BURDEN AS A CRITICAL PROGNOSTIC FACTOR OF PRIMARY EXTRAMEDULLARY DISEASE
by: M. Vlachová, et al.
Published: (2022-06-01)

A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity
by: Diana I. Albu, et al.
Published: (2024-12-01)

PD-L1-expressing natural killer cells predict favorable prognosis and response to PD-1/PD-L1 blockade in neuroblastoma
by: Mengjia Song, et al.
Published: (2024-12-01)

Gene expression and soluble protein level of PD-1 and its ligands (PD-L1 and PD-L2) in endometrial cancer.
by: Mohd Nazzary Mamat Yusof, et al.
Published: (2025-01-01)

High Quality Performance of Novel Immunoassays for the Sensitive Quantification of Soluble PD-1, PD-L1 and PD-L2 in Blood
by: Kimberly Krueger, et al.
Published: (2022-09-01)

Increased PD-1 expression in livers associated with PD-1-antibody-induced hepatotoxicity
by: Miro Saarela, et al.
Published: (2025-01-01)

Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders
by: Xintong Li, et al.
Published: (2024-11-01)

PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy
by: Xiaohui Ren, et al.
Published: (2024-04-01)

Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1
by: Mengzhen Jiang, et al.
Published: (2023-12-01)

Immunohistochemical Study of the PD-1/PD-L1 Pathway in Cutaneous Lupus Erythematosus
by: Zsófia Király, et al.
Published: (2022-08-01)

An extension of cancer immunotherapy with dostarlimab, the PD1-PD L1 pathway blocker
by: Sitangshu Sekhar Biswas, et al.
Published: (2023-12-01)

IMMUNE RESISTANCE VIA A PD-1/PD-L1 MECHANISM IN GLIOBLASTOMA
by: V.S. KUSHNIROVA, et al.
Published: (2023-12-01)

Research progress of oncolytic virus combined with PD-1/PD-L1 inhibitors
by: GAN Zi-ying, TANG Hui
Published: (2022-04-01)

Quantification of Pharmacokinetic Profiles of PD-1/PD-L1 Antibodies by Validated ELISAs
by: Sara Zalba, et al.
Published: (2020-06-01)

The PD-1/PD-L1 Pathway: A Perspective on Comparative Immuno-Oncology
by: Sandra Schöniger, et al.
Published: (2022-10-01)

Prospect of Tumor Treatment in the Post-PD-1/PD-L1 Inhibitor Era
by: SHAN Baoen
Published: (2023-09-01)